regn

Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion

[PR Newswire] – TARRYTOWN, N.Y., Feb. 24, 2014 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company’s supplemental Biologics License Applicati moreView todays social media effects on REGNView the latest stocks trending across Twitter. Click to view dashboardSee who Regeneron is hiring next, click here to […]

[$$] Research Reports

moreView todays social media effects on REGNView the latest stocks trending across Twitter. Click to view dashboardSee who Regeneron is hiring next, click here to view […]

Regeneron Announces Upcoming 2014 Investor Conference Presentations

[PR Newswire] – TARRYTOWN, N.Y., Feb. 14, 2014 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences: 2014 RBC Capital Markets’ Global … moreView todays social media effects on REGNView the latest stocks trending across Twitter. Click to view dashboardSee who Regeneron is hiring next, click here to view […]

Regeneron Pharmaceuticals’ CEO Discusses Q4 2013 Results – Earnings Call Transcript

[at Seeking Alpha] – Leonard S. Schleifer Thank you, Michael, and good morning to everyone. 2013 was another great year for Regeneron. The EYLEA franchise continue to grow steadily in the U.S. and globally our late-stage pipeline … moreView todays social media effects on REGNView the latest stocks trending across Twitter. Click to view dashboardSee who Regeneron is hiring next, […]